These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15967259)

  • 1. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder.
    Michel MC; de la Rosette JJ; Piro M; Schneider T
    Eur Urol; 2005 Jul; 48(1):110-5. PubMed ID: 15967259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The responsiveness of the OAB-q among OAB patient subgroups.
    Coyne KS; Matza LS; Thompson C; Jumadilova Z; Bavendam T
    Neurourol Urodyn; 2007; 26(2):196-203. PubMed ID: 17016794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder?
    Michel MC; de la Rosette JJ; Piro M; Goepel M
    J Urol; 2004 Aug; 172(2):601-4. PubMed ID: 15247741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.